The role of genius is not to complicate the simple, but to simplify the complicated.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
@jl, your insight has been missed.
Will it ever be possible to understand how the plague is reduced? I mean, it's obvious when a dentist removes plaque how the process occurs. But how does EPA do it?
Wondering aloud, should EPA be added to toothpaste, mouth rinse?
Thank you for the indulgence, I had conflated disposition with deposition.
"Nothing will happen in that case until 14 days after disposition of the main appeal..."
14 days after disposition, what will have changed?
remember jonathan rowe? https://www.linkedin.com/in/jonathanrowephd/
Inventors: Rowe; Jonathan; (Waterford, CT) ; Duffy; Kevin; (Dublin, IE) ; Climax; John; (Dublin, IE)
Applicant:
Afimmune Limited
Dublin
IE
https://pubchem.ncbi.nlm.nih.gov/compound/15_S_-Hepe
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=AANM%2F%22DS+Biopharma%22&Refine=Refine+Search&Query=AANM%2F%22Afimmune%22
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=0&f=S&l=50&d=PG01&OS=AANM%2F%22Afimmune%22&RS=AANM%2F%22Afimmune%22&TD=7&Srch1=%28%2522Afimmune%2522.AANM.%29&StartNum=&Refine=Refine+Search&Query=AANM%2F%22Afimmune%22
Ronan lambe and John climax
https://www.businesswire.com/news/home/20180727005016/en/ICON-Confirms-Retirement-Co-Founder-Dr.-Ronan-Lambe
During the fiscal year ending May 31, 2005, Amarin contracted ICON Clinical Research Limited (a wholly owned subsidiary of ICON), to conduct a clinical trial on its behalf. The total potential value of this study is $7 million. During the year ended December 31, 2008, the Company recognized $0.2 million of revenue relating to the Amarin contract. At December 31, 2008, $0.3 million was outstanding to be received from Amarin on this trial.
http://www.sec.gov/Archives/edgar/data/1060955/000118811209000777/t64807_20f.htm
Sunninghill Limited / JOHN CLIMAX
https://ie.globaldatabase.com/company/ds-biopharma-limited
https://investor.amarincorp.com/static-files/a59dd48b-b2ba-43ee-b64a-d02f46e191b6
https://investor.amarincorp.com/news-releases/news-release-details/amarin-announces-completion-70-million-private-placement
Sunninghill Limited / JOHN CLIMAX participated in the $70M funding, $2M @0.90/share
Just needed another 6 months of reduce-it trial time, didnt we?
why so much eagerness to sell under $7? can't you see there's sufficient buying to get more for your sale?
or is buy-to-cover transactions?
Nahmias and tenOever spent the last three months studying what SARS-CoV-2 is doing to human lung cells. What they found is that the novel coronavirus prevents the routine burning of carbohydrates, which results in large amounts of fat accumulating inside lung cells – a condition the virus needs to reproduce.
Large amount of fat accumulation inside lung cells, is this referring to triglycerides?
“By understanding how the SARS-CoV-2 controls our metabolism, we can wrestle back control from the virus and deprive it from the very resources it needs to survive,” Nahmias said, noting that it also may help explain why patients with high blood sugar and cholesterol levels are often at a particularly high risk to develop COVID-19.
The team then reviewed a panel of eight already-approved drugs that could possibly interfere with the virus’s ability to reproduce. Tricor caused the cells to start burning fat, Nahmias said. The result was that the virus almost completely disappeared within only five days of treatment.
8 already approved drugs, approved where, in Israel?
I cannot tell, since Fenofibrate work well, does this mean Vascepa will also?
Fish and Richardson PC?
IP Address: 209.222.82.228
Hostname: outbound-ip31a.ess.barracuda.com
Name=amarincorp.com, QTYPE=MX
Mail Exchange=d107598a.ess.barracudanetworks.com
IP Addresses: 68.172.228.179
Hostname: cpe-68-172-228-179.nj.res.rr.com
IP Addresses: 73.222.97.32
Hostname: c-73-222-97-32.hsd1.ca.comcast.net
IP Addresses: 216.58.166.107
ssl-cert: Subject: commonName=gpvpn.fr.com/organizationName=Fish and Richardson PC/stateOrProvinceName=Massachusetts/countryName=US
| Subject Alternative Name: DNS:gpvpn.fr.com
IP Addresses: 174.199.0.185
Hostname: 185.sub-174-199-0.myvzw.com
"A Return to Homeostasis: The Pleiotropic Effects of Eicosapentaenoic Acid (EPA) "
Well, maybe the rest if the world, outside this board's members, is finally catching on ...
Where's those results? Cha-ching
"The key is direct and indirect damage to the endothelial cells that line the blood vessels, particularly in the lungs, explains Peter Carmeliet, a vascular biologist at the Belgian research institute VIB and co-author of a 21 May paper in Nature Reviews Immunology. By attacking those cells, COVID-19 infection causes vessels to leak and blood to clot. Those changes in turn spark inflammation throughout the body and fuel the acute respiratory distress syndrome (ARDS) responsible for most patient deaths."
https://www.sciencemag.org/news/2020/06/blood-vessel-attack-could-trigger-coronavirus-fatal-second-phase?utm_campaign=ScienceNow&utm_medium=Facebook&utm_source=JHubbard
https://clinicaltrials.gov/ct2/show/NCT04221217
Interesting
Vascepa dosage, not epadel dosage
Once daily after breakfast, not twice daily
Triglycerides between 150 and 500
What am I missing ... It seems they are running the Anchor trial again?
Chloroquine or hydroxychloroquine (HCQ), with or without an antibiotic, in hospitalized COVID-19 patients were associated with increased risk of death in the hospital and higher rates of arrhythmias, analysis of outcomes in nearly 100,000 patients indicated.
The 15,000 patients who received HCQ or chloroquine were about twice as likely to die compared to controls who did not receive these agents after adjusting for covariates (18.o% for hydroxychloroquine and 16% for chloroquine versus 9.3% for controls), reported Mandeep Mehra, MD, of Brigham and Women's Hospital in Boston, and colleagues.
https://www.medpagetoday.com/infectiousdisease/covid19/86642?xid=nl_mpt_DHE_2020-05-23&eun=g207787d0r
Com'on Vascepa,, you can do it!
"Obviously assuming the trial indicates efficacy or trend towards efficacy (it is only a 2 week course after all) and so justifies a more thorough, longer course of treatment. "
P.s. let us ask NIH to fund a longer Vascepa covid-19 trial just like hydrochloroquie and azithromycin.
ha, HAAA! maybe vascepa will INTERSEPT covid-19.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155401088
"Will hospitals see cost savings from Vascepa patients needing less revascularization?"
I believe this would be more accurately stated as, will health systems incur revenue reductions from Vascepa patients needing less revascularization?
REDUCE-IT: Fewer Procedures Alone Points to Vascepa Benefit
— Will hospitals see cost savings from Vascepa patients needing less revascularization?
https://www.medpagetoday.com/meetingcoverage/scai/86502?xid=nl_mpt_DHE_2020-05-15&eun=g207787d0r
I would be tight lipped too.
Vascepa API manufacturers are located in foreign countries, countries which could decide to restrict exportation of icosapent ethyl should icosapent ethyl be proven to improve covid-19 outcomes.
21x -
COVID-19 No Worse Than the Flu? Hardly
— New York City data show dramatic imbalance
https://www.medpagetoday.com/infectiousdisease/covid19/86176
sorry, did not catch it in time.
"Selected post is > 48 hours old"
the INTERSEPT (Investigating Nutritional Therapy with EPA, GLA and Antioxidants Role in Sepsis Treatment) study
Abstract
INTRODUCTION:
Enteral nutrition (EN) with eicosapentaenoic acid (EPA)/?-linolenic acid (GLA) is recommended for mechanically ventilated patients with severe lung injury. EPA/GLA has anti-inflammatory benefits, as evidenced by its association with reduction in pulmonary inflammation, improvement in oxygenation and improved clinical outcomes in patients with severe forms of acute lung injury. This study was a prospective, multicenter, randomized, double-blinded, controlled trial designed to investigate whether EPA/GLA could have an effective role in the treatment of patients with early sepsis (systemic inflammatory response syndrome with confirmed or presumed infection and without any organ dysfunction) by reducing the progression of the disease to severe sepsis (sepsis associated with at least one organ failure) or septic shock (sepsis associated with hypotension despite adequate fluid resuscitation). Secondary outcomes included the development of individual organ failure, increased ICU and hospital length of stay, need for mechanical ventilation and 28-day all-cause mortality.
METHODS:
Randomization was concealed, and patients were allocated to receive, for seven days, either an EPA/GLA diet or an isocaloric, isonitrogenous control diet not enhanced with lipids. Patients were continuously tube-fed at a minimum of 75% of basal energy expenditure × 1.3. To evaluate the progression to severe sepsis and/or septic shock, daily screening for individual organ failure was performed. All clinical outcomes were recorded during a 28-day follow-up period.
RESULTS:
A total of 115 patients in the early stages of sepsis requiring EN were included, among whom 106 were considered evaluable. Intention-to-treat (ITT) analysis demonstrated that patients fed the EPA/GLA diet developed less severe sepsis and/or septic shock than patients fed the control diet (26.3% versus 50%, respectively; P = 0.0259), with similar results observed for the evaluable patients (26.4% versus 50.9% respectively; P = 0.0217). The ITT analysis demonstrated that patients in the study group developed cardiovascular failure (36.2% versus 21%, respectively; P = 0.0381) and respiratory failure (39.6% versus 24.6%, respectively; P = 0.0362) less often than the control group. Similarly, when considering only the evaluable patients, fewer patients developed cardiovascular failure (20.7% versus 37.7%, respectively; P = 0.03) and respiratory failure (26.4% versus 39.6%, respectively; P = 0.04). The percentage of patients fed the EPA/GLA diet requiring invasive mechanical ventilation was reduced compared with controls (ITT patients: 18.9% versus 33.9%, respectively; P = 0.394; evaluable patients: 17.5% versus 34.5%, respectively; P = 0.295). Patients nourished with the EPA/GLA diet remained in the ICU fewer days than the control population (ITT patients: 21.1 ICU-free days versus 14.7 ICU-free days, respectively; P < 0.0001; evaluable patients: 20.8 ICU-free days versus 14.3 ICU-free days, respectively; P < 0.0001) and fewer days at the hospital (ITT patients: 19.5 hospital-free days versus 10.3 hospital-free days, respectively; P < 0.0001; evaluable patients: 19.1 hospital-free days versus 10.2 hospital-free days, respectively; P < 0.001) (all numbers expressed as means). No significant differences in 28-day all-cause mortality were observed (ITT patients: 26.2% EPA/GLA diet versus 27.6% control diet, respectively; P = 0.72; evaluable: 26.4 EPA/GLA diet versus 30.18 control diet, respectively; P = 0.79).
CONCLUSIONS:
These data suggest that EPA/GLA may play a beneficial role in the treatment of enterally fed patients in the early stages of sepsis without associated organ dysfunction by contributing to slowing the progression of sepsis-related organ dysfunction, especially with regard to cardiovascular and respiratory dysfunction.
https://www.ncbi.nlm.nih.gov/pubmed/21658240
COVID enough?
Enteral nutrition (EN) with eicosapentaenoic acid (EPA)/?-linolenic acid (GLA) is recommended for mechanically ventilated patients with severe lung injury. EPA/GLA has anti-inflammatory benefits, as evidenced by its association with reduction in pulmonary inflammation, improvement in oxygenation and improved clinical outcomes in patients with severe forms of acute lung injury.
B-I-N-G-O, and bingo was his name
https://pubmed.ncbi.nlm.nih.gov/21658240/?from_term=eicosapentaenoic+acid+sepsis&from_pos=7
"I guess Amarin is able to produce some cheap version of brand Vascepa as a generic if that is the case...a with this version they can easily compete with other generics"
in addition, if amarin markets the first generic vascepa, amarin gets the vast majority of the generic vascepa market as well as what remains to the branded vascepa market. it's a method to continue getting practically all the revenues that vascepa generates in the US, both branded AND generic.
oh sh!t. he said "covid-19"
PCI Down 38% During COVID-19 Pandemic
— Where have all the missing heart attacks gone
https://www.medpagetoday.com/infectiousdisease/covid19/85922?xid=nl_mpt_DHE_2020-04-13&eun=g207787d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=Daily%20Headlines%20Top%20Cat%20HeC%20%202020-04-13&utm_term=NL_Daily_DHE_dual-gmail-definition
"I was just thinking yesterday of where is DTC ads green light? I was thinking, even under current conditions, AMRN has to really push the DTC ads when they have the go-ahead. I mean REALLY push it!"
hear, hear! there may never be another period in our lifetimes when so many people are locked in, watching so much television. run the ADs!!
what trademark will be impacted?
i know generics business model does not include advertising, but let us ignore that for the moment.
why couldn't generics run commercials exactly alike in content to those commercials that amarin is running currently. the ones with, "discuss the new trial results with your doctor" or something to that effect?
market closed. yesterday's trades
post market $6+ trading